GLP-1 drugs reduced the odds of new alcohol-use disorders by 18%, cannabis-use disorders by 14%, cocaine use by 20%, nicotine use by 26%, and opioid use by 25%, the researchers found
By 2019, 3.33 million global cases of AF contributed to over 219,000 deaths each year
No certificate of analysis
On average, tirzepatide led to 20.2% weight loss compared to 13.7% with semaglutide over 72 weeks of treatment
Understanding GLP-1 Agonists GLP-1 agonists are a key part of this new wave
Semaglutide can improve your metabolic health and assist with adhering to a low-calorie diet, as well as provide a convenient solution for weight management